COLLEGIUM PHARMACEUTICAL, INC

COLL - CIK 0001267565

Market cap$1.13 B

Rank#2551

SEC filings849

COLLEGIUM PHARMACEUTICAL, INC trades as COLL and has a market capitalization of $1.13 B, making it the #2551 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $780.57M, up 23.6% from the prior year and net income of $63.00M. This page tracks COLLEGIUM PHARMACEUTICAL, INC through 849 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$780.57MFY 2025

Net income (latest FY)$63.00MFY 2025

Operating cash flow (latest FY)$329.32MFY 2025

Total assets (latest FY)$1.66BFY 2025

Gross margin59.3%latest FY

Net margin8.1%latest FY

Financial performance

Over the last 9 fiscal years COLLEGIUM PHARMACEUTICAL, INC's revenue grew from $1.71M to $780.57M, a compound annual growth rate of 97.5%. Net profit margin expanded from -5504.1% to 8.1% over the same period - every figure below comes from the company's audited annual filings.

COLL annual revenueView details

Key statistics

Market cap: $1.13 B
Share price (derived)market cap / shares outstanding: $34.80
P/E ratio (trailing FY): 17.9
EPS (diluted)FY 2025: $1.73
Shares outstandingas of 2026-04-30: 0.03B
Total equityas of 2026-03-31: $312.42M
Return on equity: 20.2%
Cash & equivalentsas of 2026-03-31: $268.65M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-20
Insider trade	4	2026-05-18
New insider ownership	3	2026-05-18
Insider sale notice	144	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18
Insider trade	4	2026-05-18

Browse the full filing history (849 filings)

Recent press releases

Collegium to Participate in 2026 Jefferies Global Healthcare Conference2026-05-27
Collegium to Participate in 2026 Jefferies Global Healthcare Conference – Collegium Pharmaceutical Inc.
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics2026-05-12
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics – Collegium Pharmaceutical Inc.
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress2026-05-07
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress – Collegium Pharmaceutical Inc.
Collegium to Report First Quarter 2026 Financial Results on May 7, 20262026-04-23
To access the conference call, please dial (877) 407-8037 ( U.S. ) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2026 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com . The webcast will be available for replay on the Company’s website approximately two hours after the event.
Collegium to Participate in Upcoming Investor Conferences2026-04-08
Collegium to Participate in Upcoming Investor Conferences – Collegium Pharmaceutical Inc.

Similar companies

The largest companies sharing COLLEGIUM PHARMACEUTICAL, INC's SEC industry classification (pharmaceutical preparations).

LLYEli Lilly and Company$1.072 T COLL vs LLY

JNJJohnson & Johnson$573.98 B COLL vs JNJ

ABBVAbbVie Inc.$399.47 B COLL vs ABBV

MRKMerck & Co., Inc.$293.16 B COLL vs MRK

AZNAstraZeneca PLC$286.27 B COLL vs AZN

Frequently asked questions

What is COLLEGIUM PHARMACEUTICAL, INC's market cap?

COLLEGIUM PHARMACEUTICAL, INC (COLL) has a market capitalization of $1.13 B as of 2026-06-10, ranking #2551 among US-listed companies.

How much revenue does COLLEGIUM PHARMACEUTICAL, INC make?

COLLEGIUM PHARMACEUTICAL, INC reported revenue of $780.57M for fiscal year 2025, an increase of 23.6% year over year.

Is COLLEGIUM PHARMACEUTICAL, INC profitable?

Yes. COLLEGIUM PHARMACEUTICAL, INC reported net income of $63.00M in its latest fiscal year.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.